expand_moreexpand_lessexpand_moreexpand_less
|
 |
Ekta BagriQuartz |
BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk,...
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.
BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are...
login
who are we?
contact us
qosheapp
